Currently, there are 75.50M common shares owned by the public and among those 48.50M shares have been available to trade.
The company’s stock has a 5-day price change of -4.94% and 13.60% over the past three months. RCUS shares are trading -10.37% year to date (YTD), with the 12-month market performance down to -14.78% lower. It has a 12-month low price of $12.95 and touched a high of $22.68 over the same period. RCUS has an average intraday trading volume of 714.46K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.49%, 10.28%, and 4.81% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Arcus Biosciences Inc (NYSE: RCUS) shares accounts for 54.16% of the company’s 75.50M shares outstanding.
It has a market capitalization of $1.57B and a beta (3y monthly) value of 0.89. The earnings-per-share (ttm) stands at -$3.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.45% over the week and 6.03% over the month.
Earnings per share for the fiscal year are expected to increase by 24.38%, and -47.40% over the next financial year. EPS should grow at an annualized rate of 7.80% over the next five years, compared to -23.70% over the past 5-year period.
Looking at the support for the RCUS, a number of firms have released research notes about the stock. BofA Securities stated their Neutral rating for the stock in a research note on November 18, 2022, with the firm’s price target at $33. Morgan Stanley coverage for the Arcus Biosciences Inc (RCUS) stock in a research note released on October 11, 2022 offered a Overweight rating with a price target of $40. BTIG Research was of a view on October 15, 2021 that the stock is Buy, while Berenberg gave the stock Buy rating on November 24, 2020, issuing a price target of $50. Evercore ISI on their part issued Outperform rating on November 23, 2020.
